Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US6562861 | BIOCRYST | Substituted cyclopentane and cyclopentene compounds useful as neuraminidase inhibitors |
Dec, 2023
(10 months from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10391075 | BIOCRYST | Antiviral treatments |
Feb, 2027
(4 years from now) | |
US8778997 | BIOCRYST | Antiviral treatments |
May, 2027
(4 years from now) |
Market Authorisation Date: 19 December, 2014
Treatment: Treatment of acute uncomplicated influenza in patients 2 years and older; Treatment of acute uncomplicated influenza in patients 6 months and older; Treatment of acute uncomplicated influenza in adults
Dosage: SOLUTION;INTRAVENOUS
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic